Results from the DAPT-MVD trial, while not necessarily generalizable, do open the door to a new tactic in select cases.

Without changes, including initiatives that help everyone at risk, past progress in slowing IHD’s damage may be further ...

The pilot study provides “a good illustration of how AI can be an augmentation to our current processes,” Thomas Maddox says.

The US Food and Drug Administration has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for reducing LDL ...

More than one in 10 patients with no coronary calcium had noncalcified plaque, putting them at greater risk for MACE.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

Recommendations around dosing, duration, and patient-specific options are woven into the fabric of the scientific statement.

Differences in various efficiency metrics were modest, but “minutes matter in stroke,” Shyam Prabhakaran says.

Long contraindicated in patients with severe AS, the vasodilator may improve image quality with careful monitoring.

It’s critical to focus on treatment intensification, and not just initiation, in high-risk patients, Ambarish Pandey says.

The findings should lead to changes in practice, David Cohen says, but as seen in the setting of PCI, “old habits die hard.” ...

The tools may help address underdiagnosis in this area, though there is still room for improvement in screening performance.